A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Exclusion Criteria

• •Circulating lymphoma cells, defined by out-of-range (high) absolute lymphocyte count (ALC) or the presence of abnormal cells in the peripheral blood signifying circulating lymphoma cells
• •Participants with known acute bacterial, viral, or fungal infection 72 hours prior to glofitamab infusion
• •Participants with known active infection or reactivation of a latent infection
• •Pregnant, breastfeeding, or intending to become pregnant during the study
• •Prior treatment with systemic immunotherapeutic agents
• •History of treatment-emergent, immune-related adverse events (AEs) associated with prior immunotherapeutic agents
• •Persistent AEs from prior anti-cancer therapy Grade \>=1
• •Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with any other investigational or approved anti-cancer agent
• •Prior solid organ transplantation
• •Prior allogeneic stem cell transplant (SCT)
• •Autologous SCT within 100 days prior to obinutuzumab infusion
• •Autoimmune disease in active phase or exacerbation/flare within at least 6 months of enrollment
• •History of immune deficiency disease that increases the risk of infection
• •History of contraindication and/or severe allergic or anaphylactic reactions to monoclonal antibody therapy and/or prophylactic drugs used for cytokine release syndrome (CRS) and tumor lysis syndrome (TLS)
• •History of confirmed progressive multifocal leukoencephalopathy
• •Current or past history of central nervous system (CNS) lymphoma or CNS disease
• •Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
• •Major surgery or significant traumatic injury \<28 days prior to the GpT infusion or anticipation of the need for major surgery during study treatment
• •Participants with another invasive malignancy in the last 2 years
• •Significant cardiovascular disease
• •Administration of a live, attenuated vaccine within 4 weeks before GpT infusion or anticipation that such a live attenuated vaccine will be required during the study
• •Received systemic immunosuppressive medications for reasons other than anticancer therapy within the last 6 months of enrollment with the exception of corticosteroid treatment \<= 25 mg/day prednisone or equivalent
• •History of illicit drug or alcohol abuse within 12 months prior to screening, in the Investigator's judgment
• •Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug